Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy
Klochkov S. G., Neganova M. E., Yarla N. S., Parvathaneni M., Sharma B., Tarasov V. V., Barreto G., Bachurin S. O., Ashraf G. M., Aliev G.
Seminars in Cancer Biology
Vol.56, P. 128-134
Опубликовано: 2019
Тип ресурса: Обзор
DOI:10.1016/j.semcancer.2017.10.010
Аннотация:
Ras proteins have been reported to play key role in oncologic diseases. Ras proteins are associated with cellular membranes for its carcinogenic activities through post-translational modifications, including farnesylation. Farnesyltransferase is responsible for a type of Ras membrane targeting, which leads to cancer origin and progression. Inhibitors of farnesyltransferase have been developed as novel anticancer agents. In this review, the role of farnesyltransferase in cancer progression and development has been discussed. Further, the current status of development of farnesyltransferase inhibitors for cancer prevention and treatment has also been reviewed. © 2017 Elsevier Ltd
Ключевые слова:
Cancer; Farnesyltransferase; Farnesyltransferase inhibitor; Ras protein; Therapy
3 benzyl 7 cyano 2,3,4,5 tetrahydro 1 (1h imidazol 4 ylmethyl) 4 (2 thienylsulfonyl) 1h 1,4 benzodiazepine; alpha hydroxyfarnesylphosphonic acid; cisplatin; cyclophosphamide; doxorubicin; gemcitabine; l 778123; lonafarnib; manumycin; manumycin A; n [[5 [(2 amino 3 mercaptopropyl)amino][1,1' biphenyl] 2 yl]carbonyl]methionine methyl ester; phytoene synthase; protein farnesyltransferase; protein farnesyltransferase inhibitor; tipifarnib; unclassified drug; antineoplastic agent; enzyme inhibitor; farnesyl trans transferase; protein binding; acute myeloid leukemia; antineoplastic activity; bone marrow suppression; cancer growth; cancer prevention; cancer therapy; carcinogenesis; drug classification; drug safety; drug tolerance; enzyme specificity; fatigue; gastrointestinal symptom; molecular docking; neutropenia; oncogene ras; peripheral neuropathy; protein function; protein processing; Review; thrombocytopenia; animal; clinical trial (topic); gene expression regulation; human; metabolism
Язык текста: Английский
ISSN: 1096-3650
Klochkov S. G.
Neganova M. E.
Yarla N. S.
Parvathaneni M.
Sharma B.
Tarasov V. V. Vadim Vladimirovich 1987-
Barreto G.
Bachurin S. O.
Ashraf G. M.
Aliev G. Gyumrakh 1958-
Клочков С. Г.
Неганова М. Е.
Ярла Н. С.
Парватханени М.
Шарма Б.
Тарасов В. В. Вадим Владимирович 1987-
Баррето Г.
Бачурин С. О.
Ашраф Г. М.
Алиев Г. Гюмрах 1958-
Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy
Текст визуальный непосредственный
Seminars in Cancer Biology
Academic Press
Vol.56 P. 128-134
2019
Обзор
Cancer Farnesyltransferase Farnesyltransferase inhibitor Ras protein Therapy
3 benzyl 7 cyano 2,3,4,5 tetrahydro 1 (1h imidazol 4 ylmethyl) 4 (2 thienylsulfonyl) 1h 1,4 benzodiazepine alpha hydroxyfarnesylphosphonic acid cisplatin cyclophosphamide doxorubicin gemcitabine l 778123 lonafarnib manumycin manumycin A n [[5 [(2 amino 3 mercaptopropyl)amino][1,1' biphenyl] 2 yl]carbonyl]methionine methyl ester phytoene synthase protein farnesyltransferase protein farnesyltransferase inhibitor tipifarnib unclassified drug antineoplastic agent enzyme inhibitor farnesyl trans transferase protein binding acute myeloid leukemia antineoplastic activity bone marrow suppression cancer growth cancer prevention cancer therapy carcinogenesis drug classification drug safety drug tolerance enzyme specificity fatigue gastrointestinal symptom molecular docking neutropenia oncogene ras peripheral neuropathy protein function protein processing Review thrombocytopenia animal clinical trial (topic) gene expression regulation human metabolism
Ras proteins have been reported to play key role in oncologic diseases. Ras proteins are associated with cellular membranes for its carcinogenic activities through post-translational modifications, including farnesylation. Farnesyltransferase is responsible for a type of Ras membrane targeting, which leads to cancer origin and progression. Inhibitors of farnesyltransferase have been developed as novel anticancer agents. In this review, the role of farnesyltransferase in cancer progression and development has been discussed. Further, the current status of development of farnesyltransferase inhibitors for cancer prevention and treatment has also been reviewed. © 2017 Elsevier Ltd